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Abstract
Background: We evaluate trade-offs between quality of life (QoL) and survival improvement for two chemotherapy
regimens in advanced breast cancer. We also report on the long-term survival of patients in the ANZ 8614 clinical
trial.
Methods: A total of 391 patients were randomized to mitoxantrone (14 mg/m2 intravenously every 21 days) or a
combination of cyclophosphamide 100 mg/m2 and prednisone 40 mg/m2 orally days 1 to 14 plus methotrexate
40 mg/m2 and 5-fluorouracil 600 mg/m2 intravenously days 1 and 8 every 28 days (CMFP). QoL was self-assessed
on 14 linear analog scales. We computed the mean differences between the two treatments as products of the
mean differences in global QoL, progression-free survival and overall survival.
Results: CMFP led to a higher overall tumor response (39% vs. 25%, P=0.004) and longer progression-free survival
(PFS) (median 5.6 vs 3.9 months, P=0.02) but with significantly more toxicity from alopecia, mucositis, diarrhea,
anemia and lethargy. Overall survival (OS) was similar in the two groups (median 10.1 vs 11.6 months, P=0.81). QoL
over the first 12 weeks was rated better by patients on CMFP for mood (P=0.04), nausea and vomiting (P=0.01), and
feeling sick (P=0.02) but worse for hair loss (P<0.0001). A weighted combination of individual QoL items favoured
CMFP (subset score mean difference 2.4, P=0.03). A global QoL score tended to favour CMFP (global score mean
difference 1.7, P=0.18). Quality-adjusted PFS was significantly longer with CMFP (mean 7.208 vs 5.965 months, P=0.04),
but quality-adjusted OS was not significantly different (mean 11.832 vs 11.315 months, P=0.57).
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Conclusion: Despite the greater toxicity, the superior antitumor activity of CMFP led to an overall improvement in
quality-adjusted PFS. In advanced breast cancer, in clinical decision making about treatment for palliative intent, the
principle used to assess trade-offs between antitumor efficacy and toxicity remains relevant and applicable to all
modern therapeutic agents.
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Background
Most patients with advanced breast cancer will die as
a result of their disease. Systemic treatment is usually
administered with palliative intent, with the aims of
prolonging overall survival (OS), and improving
patient symptoms and quality of life (QoL). With
recent new breast cancer therapeutic agents, there
have been modest but meaningful improvements in
OS (Chia et al. 2007; Gennari et al. 2005; Dafni et al.
2010). However, improvements in symptoms and QoL
remain important goals for this incurable disease
(Chung and Carlson 2003).
A recent Cochrane review reported that combination
chemotherapy resulted in significant prolongation of OS
and time to progression and superior tumor response
but more toxicity in women with metastatic breast
cancer (Carrick et al. 2009). Our previous studies de-
monstrated that QoL can be improved through chemo-
therapy despite its treatment-related toxicity (Coates et al.
1987; Stockler et al. 2011). It has been suggested that
further improvement in patient outcomes could be
achieved by using treatments of low toxicity with the
focus on trade-off between QoL and OS (Tannock
1987). However, the interpretation of such a clinical
trial could be complicated, particularly when a treat-
ment improves one clinical endpoint, such as QoL,
but disadvantages the other, such as OS.
Using data from ANZ 8614 clinical trial (Simes et al.
1994; Bishop et al. 1999; Carrick et al. 2009; Lord et al.
2008), we evaluate trade-offs between QoL and
survival improvement, in terms of quality-adjusted
survival outcomes, by comparing patients with
advanced breast cancer treated with single-agent
mitoxantrone and combination cyclophosphamide,
methotrexate, 5-flurouracil, and prednisone (CMFP).
Mitoxantrone has some clinical activity in advanced
breast cancer, is easy to administer and is relatively
low in toxicity (Cornbleet et al. 1984). CMFP, on the
other hand, is a more complex regimen with esta-
blished activity and possible greater toxicity than
mitoxantrone. In this report, we also provide up-
dated long-term survival outcomes of the ANZ 8614
clinical trial (Simes et al. 1994; Bishop et al. 1999;
Carrick et al. 2009; Lord et al. 2008).
Methods
Patients
Key eligibility criteria included histologically confirmed
breast carcinoma, with recurrent or metastatic mea-
surable or evaluable disease, adequate bone marrow re-
serves (white blood cell count of 4.0 × 109/L or greater
and platelet count of 100 × 109/L or greater), adequate
hepatic (serum bilirubin less than 20 mol/L) and renal
function (creatinine less than 0.15 mmol/L), and an
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status of 0 to 3. Key exclusion criteria were prior
cytotoxic chemotherapy for recurrent or metastatic
breast cancer, extensive radiotherapy, past history of
other cancer, diabetes mellitus, congestive cardiac fai-
lure, and symptomatic coronary artery disease. All
patients provided signed written informed consent.
Random assignment was performed centrally and ba-
lanced dynamically for the treating institution, perfor-
mance status (ECOG PS 0 to 1 vs 2 to 3), and the
presence of liver or brain metastases. Patients were
randomly assigned to receive either mitoxantrone or
CMFP. On treatment failure, crossover to the other
treatment regimen was allowed as second-line therapy
for all patients.
Treatments
Mitoxantrone was given intravenously in a dose of 14
mg/m2, repeated every 21 days. CMFP consisted of oral
cyclophosphamide 100 mg/m2 and oral prednisone 40
mg/m2 daily on days 1 through 14, with methotrexate 40
mg/m2 and 5-fluorouracil 600 mg/m2 administered
intravenously on days 1 and 8 and repeated every 4
weeks.
Doses were based on surface area calculated from the
lesser of ideal or actual body weight. Treatment was de-
layed until toxicities other than alopecia had resolved to
grade 1 or lower. Subsequent doses of chemotherapy
were routinely adjusted on the basis of pretreatment
total white cell count (or, when available, on neutrophil
counts at the nadir of each cycle) and platelet count.
The initial chemotherapy regimen was continued until
disease progression, patient intolerance, or unacceptable
toxicity. A maximum cumulative dose of 140 mg/m2 of
mitoxantrone or a maximum 12 months of CMFP
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chemotherapy were recommended. However, beyond
these times, further treatment was allowed at the dis-
cretion of the responsible clinician, with appropriate
monitoring.
Assessments
Patients were assessed before each cycle of chemo-
therapy: every 3 weeks for those receiving mitoxantrone
and 4 weeks for CMFP. Adverse events were rated
with the World Health Organization (WHO) criteria
(Miller et al. 1981) after each cycle of chemotherapy.
Computerized axial tomographic scans of the chest
and abdomen and skeletal radionucleotide scans were
performed at baseline and every 12 weeks until di-
sease progression, or at an earlier time if disease pro-
gression was suspected.
Study design
The primary aim of this study was to determine
whether a chemotherapeutic regimen of established
efficacy but more toxicity is associated with an overall
net clinical benefit measured in terms of quality-
adjusted progression-free survival (PFS) and quality-
adjusted OS. The aim of the ANZ 8614 trial was to
compare the two randomized regimens in terms of PFS
(defined as time from randomization to progression or
death), OS (defined as time from randomization to
death), objective tumor response (complete plus partial
response), and QoL. The objective tumor response was
classified according to the WHO criteria as complete
response, partial response, no change, or progressive
disease (Miller et al. 1981).
QoL was assessed before random assignment, before
each cycle of chemotherapy up to 12 weeks, then every
12 weeks thereafter until death. Patients were asked to
rate their QoL averaged over the period since their last
assessment by using a series of linear analog self-
assessment scales. We used the five linear analog
self-assessment (LASA) scales developed by Priestman
and Baum (Priestman and Baum 1976): physical
wellbeing, mood, pain, nausea and vomiting, and appe-
tite. We also used the general life quality scales (GLQ-8)
of Coates and colleagues (Coates et al. 1990): feeling
anxious/depressed, feeling sick, numbness, hair loss,
tiredness, appetite/taste, sexual interest, the thought of
having treatment, and an overall QoL index uniscale. In
addition, at each of these times, the clinician completed
the Spitzer QL-index (Spitzer et al. 1981).
Statistical considerations
The planned sample size of 450 patients (225 per arm)
accrued over 3 years and observed for an additional
3 years was designed to give 80% power to detect a 35%
improvement in 12-month OS from 34% to 45% (hazard
ratio (HR), 0.74), comparing the mitoxantrone and CMF
groups. The final sample size of 391 patients provided
adequate power, owing to longer accrual and follow-up
periods.
We compared response and toxicity using the exact
tests for these ordered categorical data. We constructed
Kaplan-Meier curves for PFS and OS and compared
them by using the log-rank test for the analyses of these
time-to-event data. The influence of baseline factors on
treatment effects was assessed by testing for interactions
with treatment in Cox proportional-hazards models for
PFS and OS. Multivariable analyses for the baseline
factors were also undertaken. All analyses were by
intention to treat. All P values and 95% confidence inter-
vals (CIs) are two sided.
Scores on each QoL scale were compared for the two
treatment groups from randomization until first disease
progression. Missing components of QoL data were
replaced with the mean values of the treatment group.
Limited data on QoL from progression until death were
available; this was calculated as the mean of the available
QoL scores regardless of treatment group.
A global QoL score, derived using a regression func-
tion, was a weighted combination of the measured glo-
bal QoL scale (GLQ-8) and all individual LASA QoL
(except sexual interest) items. A subset QoL score was a
weighted combination of only individual LASA QoL
(except sexual interest) items. A previous publication
outlines the detailed methods of derivation of the global
and subset QoL scores (Lumley et al. 2001). A utility
score was obtained from power transformation of the
global QoL score (Lumley et al. 2001).
Measures of net clinical benefit were demonstrated by
incorporating survival and QoL outcomes into single
measures as quality-adjusted PFS and quality-adjusted
OS (Glasziou et al. 1990). Quality-adjusted PFS for each
group was the product of its mean utility score and the
area under its time-to-progression curve truncated at 24
months (Glasziou et al. 1990). We calculated the mean
utility score from randomization to disease progression
using generalized estimating equation models for each
treatment group. We used an exchangeable correlation
structure and robust standard error estimator to account
for correlation among repeated measures of QoL. The
CIs and P values for differences in quality-adjusted PFS
between groups were calculated with bootstrap methods.
A similar method was adopted for quality-adjusted OS
(where QoL after disease progression was calculated as
the average of all available QoL scores) and the area
under its time-to-death curve truncated at 30 months.
Results
Between January 1988 and June 1993, 391 patients
from 24 institutions in Australia and New Zealand
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participated in this study (Figure 1). One patient died after
randomization but before treatment started. Seven
patients were classified as ineligible after randomization.
All these eight patients were included in the primary
intention-to-treat analysis. All reported analyses are based
on 391 patients. Exclusion of the eight ineligible patients
did not materially alter the results or conclusions.
At the last data update (June 2008), the median follow-
up period was 11.6 years (range, 2 days to 11.9 years), 354
(91%) of the patients had disease progression, 37 (9%)
were known to be progression-free, 387 (99%) had died,
one was lost to follow-up and 3 (1%) were known to be
alive.
Baseline characteristics were well balanced among the
treatment groups (Table 1). The median age was
57 years; 11% were aged 70 years or older, and 45% were
aged 55 years or younger. One patient was male, 161
(41%) had liver and/or brain metastases, 28% had poor
performance status (ECOG PS 2 or 3), 19% had received
adjuvant chemotherapy, and 169 (45%) had hormone-
receptor–positive tumors, of whom 89% had undergone
previous endocrine therapy.
In the mitoxantrone group, patients received 94% of
the recommended initial dosage. Both treatment groups
had the same mean number of cycles of chemotherapy
(5.4). In the CMFP group, patients received 92% of the
recommended initial dosage of cyclophosphamide, 94%
of methotrexate, 95% of 5-flourouracil and 92% of
prednisone.
Objective tumor response
Of the 365 patients (93%) evaluable for tumor response,
confirmed complete or partial responses to initial ran-
domly assigned therapy were documented in 117 (32%).
The objective tumor response rate was significantly
greater for CMFP than mitoxantrone (39% vs 25%,
P=0.001) (Table 2).
Two-hundred and eighteen patients subsequently
crossed over to receive the other therapy at first disease
progression; 115 patients randomized to mitoxantrone
went on to receive CMFP, and 103 randomized to CMFP
went on to receive mitoxantrone. Patients who received
CMFP as second-line therapy had a significantly higher
response rate than those crossing over to mitoxantrone
(27% vs 11%, P=0.006). Over 60% of patients receiving
mitoxantrone as second-line therapy had disease pro-
gression without a prior objective tumor response or
stable disease. The probability of a response on second-
Randomly allocated
(n=391)
Allocated to mitoxantrone 
(n=197)
Allocated to CMFP
(n=194)
Ineligible (n=4)
1 previous endometrial 
cancer 
1 elevated bilirubin
2 diabetes mellitus 
Ineligible (n=3)
1 noncarcinomatous breast 
neoplasm 
2 elevated bilirubin
Died (n=193)
Alive (n=1)
Lost to follow-up (n=0)
Died (n=194)
Alive (n=2)
Lost to follow-up (n=1)
Died before treatment (n=1)
Analysed
(n=197)
Analysed
(n=194)
Figure 1 Enrolment and analysis.
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line CMFP was independent of a prior response to
mitoxantrone.
Progression-free survival and overall survival
The time to first disease progression was significantly
longer for the CMFP than the mitoxantrone group
(median PFS 5.6 vs 3.9 months; HR, 0.78; 95% CI 0.63 to
0.96; P=0.02, Figure 2A).
OS was similar in the CMFP and the mitoxantrone
groups (10.1 vs 11.6 months; HR, 0.98; 95% CI 0.80 to
1.19; P=0.81, Figure 2B).
Adverse events
Adverse events were evaluable in 377 patients (96%)
(Table 3). Adverse events of any grade occurred more
frequently in patients randomized to CMFP than
mitoxantrone, in particular for alopecia, stomatitis, diar-
rhea, lethargy/somnolence, and anemia. There was no
significant difference in leucopenia, thrombocytopenia
or nausea/vomiting between the two regimens. When
hematologic toxicity was excluded, 52 (27%) of patients
receiving CMFP compared with 15 (8%) on mito-
xantrone (P=0.0001) had at least one episode of toxicity
at grade 3 or worse.
There were 15 treatment-related deaths: 11 patients
receiving CMFP (infection 7, cardiomyopathy 1, car-
diac failure 1, myelosuppression 2) and 4 patients re-
ceiving mitoxantrone (infection 2, cardiomyopathy 1,
myelosuppression 1).
Quality of life
Three-hundred and forty-six patients (89%) had a base-
line QoL assessment with at least one follow-up assess-
ment in the first 12 weeks after randomization and were
included in the main analyses. QoL scores were not
available on 25 patients (6%) randomized to CMFP and
20 patients (5%) randomized to mitoxantrone.
Up to 12 weeks after randomization, the average change
in the scores of QoL indicators for mood (difference 3.5,
P=0.02), pain (difference 8.7, P<0.01) and feeling anxious/
depressed (difference 4.2, P<0.01) and thought of treat-
ment (difference 8.7, P<0.01) improved significantly from
baseline regardless of treatment assignment. Scores for
appetite (difference 5.8, P<0.01), nausea and vomiting
(difference 7.5, P<0.01), hair loss (difference 21.9, P<0.01),
tiredness (difference 8.4, P<0.01), and sexual interest
(difference 6.9, P<0.01), worsened significantly from base-
line. Overall QoL, rated either by the patient (GLQ-8
uniscale, P=0.26) or clinician (Spitzer QL-Index, P=0.44),
remained unchanged over this time.
When the average change in QoL in the first 12 weeks
after randomization from baseline was compared
Table 1 Baseline characteristics
Mitoxantrone CMFP
Characteristics n % n %
Age, years
<50 53 27 63 32
50–59 63 32 48 25
60–69 57 29 65 34
≥70 24 12 17 9
Unknown 0 0 1 <1
Liver or brain metastases 84 43 77 40
Interval from diagnosis of breast cancer to
diagnosis of advanced disease ≥2 years
90 46 101 52
ECOG performance status
0 58 29 58 30
1 84 43 82 42
2 38 19 41 21
3 17 9 13 7
Hormone receptor status
ER or PR positive 92 48 77 41
ER and PR negative 38 20 37 20
ER and PR unknown 62 32 73 39
Previous chemotherapy 37 19 35 18
Previous endocrine therapy 167 85 158 81
ER estrogen receptor, PR progesterone receptor.
Table 2 Tumor response to treatment
Mitoxantrone (n=187)* CMFP (n=178)* All patients (n=365)*
Objective response n % n % N %
Complete response 4 2 9 5 13 3
Partial response 43 22 61 31 104 27
Stable disease 77 39 78 40 155 40
Progressive disease 63 32 30 15 93 24
Unknown response 10 5 16 8 26 7
Response rate (of evaluable) 47 25.1% 70 39.3% 117 32.1%
* The total number of patients evaluable for response was 365 (CMFP 178, mitoxantrone 187).
CMFP, combination therapy with cyclophosphamide, methotrexate, 5-fluorouracil and prednisone.
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between the two treatment groups, patients assigned
CMFP compared with those assigned mitoxantrone re-
ported better scores for mood (difference 6.1, P=0.04),
nausea and vomiting (difference 7.3, P=0.01), and feeling
sick (difference 6.5, P=0.02), but worse scores for hair loss
(difference 20.5, P<0.01) (Figure 3). GLQ-8 uniscale scores
rated by the patient and Spitzer QL-Index scores rated by
the clinician were not significantly different between
treatments (P=0.53 and P=0.20, respectively). The subset
QoL score favored the CMFP group (difference 2.4,
P=0.03), and the global QoL score had a non-significant
trend in favor of CMPF (difference 1.7, P=0.18).
When the QoL scores were examined after ran-
domization until first disease progression, similar re-
sults were obtained as those up to 12 weeks after
randomization (results not shown).
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Figure 2 Progression-free survival (A) and overall survival (B) by treatment group, among women with advanced breast cancer treated
with mitoxantrone or CMFP (cyclophosphamide, methotrexate, 5-fluorouracil, prednisone).
Lee et al. SpringerPlus 2013, 2:391 Page 6 of 10
http://www.springerplus.com/content/2/1/391
After first disease progression, only 223 patients (57%)
had a QoL assessment. QoL scores were not available
on 84 patients (43%) randomly assigned mitoxantrone
and 84 (43%) randomly assigned CMFP. When QoL was
examined over the entire survival period from ran-
domization to death, there were no significant diffe-
rences, with the exception of hair loss, which was worse
for those randomly assigned CMFP (difference 8.7,
P<0.01).
Quality-adjusted progression-free survival and overall
survival analyses are shown in Table 4. Quality-adjusted
PFS was significantly longer in patients randomly
assigned CMFP than those assigned mitoxantrone (dif-
ference 1.243, bootstrapped 95% CI 0.119 to 2.487,
P=0.04). From first disease progression until death, the
average utility for both treatment groups was 0.847.
Quality-adjusted OS was similar for patients randomly
assigned CMFP and mitoxantrone (Table 4).
Discussion
Patients randomly assigned CMFP had significantly higher
tumor response rate (39% vs 25%, P=0.001), significantly
longer PFS (median 5.6 vs 3.9 months, P=0.02) and signifi-
cantly longer quality-adjusted PFS (mean 7.208 vs 5.965
months, P=0.04) than those assigned mitoxantrone. How-
ever, CMFP was significantly associated with at least one
episode of grade 3 or worse toxicity than mitoxantrone.
Despite the greater toxicity of CMFP, the result of this
study was consistent with our hypothesis that better
tumor control achieved with this regimen was still asso-
ciated with improved quality-adjusted PFS for these pa-
tients with advanced breast cancer.
Despite a longer PFS with CMFP, there was no advan-
tage with initial use of this regimen in terms of OS or
quality-adjusted OS. More than half of the patients
whose disease progressed on mitoxantrone were sub-
sequently treated with CMFP. Consequently, post-
progression therapy might have obscured any potential
advantage of CMFP for OS. In this setting of advanced
breast cancer, selection of one of these regimens for ini-
tial treatment could reasonably be based on improve-
ment in symptoms and QoL. Despite the additional
toxicity of CMFP chemotherapy, patients randomly
assigned this treatment reported improvement in QoL
after 3 months on therapy (Figure 3), with significant
improvement in mood, nausea and vomiting, and feeling
sick. There was a nonstatistical significant advantage in
favor of CMFP according to the global QoL score, but
the quality-adjusted PFS was also significantly longer
with CMFP.
Since the time this trial was undertaken, a wide range
of newer chemotherapeutic agents and molecularly
targeted therapies have become available as first-line
treatment for advanced breast cancer. Although neither
of the regimens investigated in this randomized trial
would now be accepted as the most efficacious first-line
therapy, this study has tested an important principle of
choosing between the more effective but more toxic
CMFP and the less effective and less toxic mitoxantrone.
Treatments that are less efficacious but also lower in
toxicity may result in fewer treatment-related side-effects,
but poor tumor control fails to improve cancer-related
symptoms, QoL or quality-adjusted survival outcomes.
The results of this study are consistent with our earlier
finding (Coates et al. 1987) that optimal patient benefit in
advanced breast cancer comes from the use of a regimen
likely to be most effective in controlling the tumor. How-
ever, when selecting treatment for individual patients, the
Table 3 Adverse events
Mitoxantrone (n=186) CMFP (n=191)
Any grade Grade 3–4 Any grade Grade 3–4
Adverse event N N n n P*
Hematuria 4 0 6 0 0.75
Stomatitis 34 2 91 21 <0.001
Nausea and vomiting 135 10 137 9 0.82
Alopecia 83 0 131 0 <0.001
Diarrhea 19 0 56 2 <0.001
Somnolence 14 0 34 2 0.003
Anemia 83 5 119 15 0.001
Leukopenia 138 56 146 60 0.64
Neutropenia 114 52 109 53 0.29
Thrombocytopenia 23 10 35 15 0.12
Other 68 4 111 30 <0.001
* P for any adverse event vs none between the two treatment groups.
CMFP, combination therapy with cyclophosphamide, methotrexate, 5-fluorouracil and prednisone.
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advantages and disadvantages of each treatment should
be considered. For example, mitoxantrone may have a
role for those patients who are relatively asymptomatic
or who have more slowly evolving forms of cancer and
for patients for whom hair loss is a primary concern.
Systematic reviews of chemotherapy in advanced
breast cancer have shown survival improvement with
combination polychemotherapy (Carrick et al. 2009),
and taxane-based chemotherapy (Ghersi et al. 2005),
and better tumor response and improved PFS with
anthracycline-based chemotherapy (Lord et al. 2008).
However, these reviews have reported that gains in sur-
vival are modest and these regimens have been asso-
ciated with additional toxicity. Even with the wide range
of modern therapies available, it remains relevant and
important that such regimens are assessed for evidence
to support a reasonable chance of providing meaningful
net clinical benefit through integration of measures of
Figure 3 Difference between quality-of-life scores between patients assigned CMFP and those assigned mitoxantrone, averaged over
the first 12 weeks relative to baseline. The subset QoL score is constructed by using information from all individual LASA QoL (except GLQ-8
and sexual interest) items and is weighted on the basis of patient-rated importance. The global QoL score is constructed by using information
from all individual LASA QoL and GLQ-8 (except sexual interest) items and is weighted on the basis of patient-rated importance.
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QoL and/or symptom control with survival outcomes as
indicators of efficacy in clinical trials.
There are ongoing concerns about the scientific rigor
of QoL outcomes and their influence on clinical deci-
sion making. A recent review of metastatic breast can-
cer trials reported that QoL outcomes provided little
information beyond that obtained from survival and
toxicity outcomes, leading to no change in recommen-
dations as the result of the additional QoL assessments
(Goodwin et al. 2003). It has been recommended that
QoL assessments would be important when treatments
have equivalent tumor-related outcomes and competing
toxicities are present or the logistics of treatment
administration differ (Goodwin et al. 2003). Our trial
results, however, are different, as CMFP is superior to
mitoxantrone in tumor-related outcomes, but CMFP is
also more toxic than mitoxantrone. In this case, the
QoL assessment by patients and the integration of indi-
vidual QoL scores according to patient weightings with
survival outcomes provided a more complete picture of
the balance of benefit and harm in guiding clinical deci-
sion making. We recommend that this approach be
adopted in other clinical trials where trade-offs in
toxicity with tumor response and survival exist.
There are several limitations of this study. Both the
experimental and control regimens are not the standard
choices of first-line therapy in today’s context. However,
these choices were reasonable at the time of conception of
this trial in the 1980s. The improvement of QoL, such as
mood, appetite, nausea, vomiting, could be resulted from
the use of prednisone as part of CMFP, but not necessary
contributing to the overall efficacy of this regimen.
Furthermore, as QoL was assessed subjectively by the
patients, some placebo effect may have been involved.
However, all patients in this trial received active therapy,
and the QoL measures used had been validated, so such
an effect, if any, could be considered negligible. Although
the global QoL score was calculated by incorporating
different QoL items according to the weighted importance
from the average trial patient’s perspective, individual
patients in other settings may have different trade-offs for
these QoL items that may vary from the average pers-
pective. A previous study did demonstrate some simila-
rity in the weights assigned for the QoL items by
patients with advanced breast cancer in different set-
tings (Lumley et al. 2001).
Conclusion
In advanced breast cancer, the main goals of treatment
are to improve symptoms and QoL. Many contemporary
chemotherapeutic and molecularly targeted agents have
different and unique side-effect profiles as compared
with the traditional regimens tested in this study. How-
ever, the principle used to assess trade-offs between the
antitumor efficacy and toxicity remains relevant and
applicable for clinical decision making today.
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Table 4 Quality-adjusted progression-free and Overall Survival
Parameter CMFP (n=194) Mitoxantrone (n=197) Difference 95% CI P*
Mean progression-free months† 7.975 6.666 1.309 0.047 to 2.648 0.05
Mean utility from randomisation to 1st disease progression 0.904 0.895 0.009 −0.006 to 0.022 0.16
Quality-adjusted progression-free survival 7.208 5.965 1.243 0.119 to 2.487 0.04
Mean overall survival months‡ 13.330 12.813 0.517 −1.266 to 2.560 0.62
Mean utility from randomisation to death 0.888 0.883 0.005 −0.007 to 0.014 0.35
Quality-adjusted overall survival 11.832 11.315 0.517 −1.120 to 2.296 0.57
* The 95% confidence interval and P value were obtained by bootstrap sampling with 1000 replications.
† Mean progression-free survival was calculated as the area under the curve for the time from randomization to first disease progression, truncated at 24 months.
‡ Mean overall survival was calculated as the area under the curve for the time from randomization to death, truncated at 30 months.
CMFP, combination therapy with cyclophosphamide, methotrexate, 5-fluorouracil and prednisone.
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